Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Senju/Mochida's Dry Eye Med Scores PIII Primary Endpoint
July 17, 2024
- LTL, Cheplapharm Envision Heightened Opportunities for LLP Takeovers under Elective Care Scheme
July 16, 2024
- Meiji Paints Consortium Plan of Its Own, Woos Generic Peers to Join Scheme
July 16, 2024
- Shonan iPark Commences Full-Fledged Operations in South Korea
July 16, 2024
- Ex-Teva Takeda Chief Matsumori to Lead Daito
July 16, 2024
- AbbVie Files Venclexta for Mantle Cell Lymphoma in Japan
July 16, 2024
- FDA Snubs MEDRx/DWTI’s Lidocaine Patch Yet Again
July 16, 2024
- Japan CGP Market Projected at 54 Billion Yen by 2035: Fuji Keizai
July 16, 2024
- Meiji Looks at Sales of 274 Billion Yen from Pharma Biz in FY2026
July 12, 2024
- Leqembi Approved in Hong Kong, Israel: Eisai
July 12, 2024
- Chiesi Joins Japan Rare Disease Market, Shoots for 10 Billion Yen Sales by 2030
July 12, 2024
- FY2023 Logs Gyration in COVID Drug Sales, Stark Contrast for Ronapreve, Lagevrio
July 11, 2024
- Taiho Bags Japan, Asian Rights to Arcus’ CD73 Inhibitor
July 10, 2024
- Mitsubishi Tanabe to Copromote Moderna’s mRNA Respiratory Vaccines
July 10, 2024
- Mounjaro Winner in May GP Rep Promotion Rankings: Intage
July 9, 2024
- Moderna Medical Chief Voices Excitement for Flu-COVID Jab; Japan PIII Set to Kick Off by Year’s End
July 9, 2024
- Shionogi Rolls Out In Vitro Diagnostic for Fetroja in Japan
July 9, 2024
- Rapalimus Granules Now Available in Japan: Nobelpharma
July 9, 2024
- FunPep to Run Additional Trial for Functional Peptide in Skin Ulcers
July 8, 2024
- Japan Ethical Drug Sales Up 4.9% in May: Crecon
July 8, 2024
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…